Insight

Drew Moghanaki: UPMC Phase II Study on H&N Cancers and the Future of Immunotherapy in ChemoRT

Drew Moghanaki/X

Jun 19, 2025, 08:12

Drew Moghanaki: UPMC Phase II Study on H&N Cancers and the Future of Immunotherapy in ChemoRT

Drew Moghanaki, Chief Medical Officer at Respirati and Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at David Geffen School of Medicine at UCLA, shared a post on X:

“From my perspective, this UPMC phase II study for H&N cancers is a landmark randomized clinical trial, even though it enrolled only 80 participants. It establishes a potentially final deterrent for investigators considering future studies combining concurrent immune checkpoint inhibitors during chemoRT for any cancer. I predict that the way forward will be sequential immunotherapy with chemoRT investigating newer drug combinations.”

Title: Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer

Authors: Dan P. Zandberg, Lazar Vujanovic, David A. Clump, Brian P. Isett, Hong Wang, Gabriel Sica, Riyue Bao, Housayin Li, James Ohr, Heath D. Skinner, Raja R. Seethala, Simion I. Chiosea, Robert L. Ferris, Julie E. Bauman

Read the Full Article.

Drew Moghanaki

More posts featuring Drew Moghanaki.

Brian P. Isett Dan P. Zandberg David A. Clump Drew Moghanaki Gabriel Sica Heath D. Skinner Hong Wang Housayin Li James Ohr Julie E. Bauman Lazar Vujanovic Raja R. Seethala Riyue Bao Robert L. Ferris Simion I. Chiosea

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More